{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T13:50:44Z","timestamp":1787061044164,"version":"build-2736575974"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2012,1]]},"DOI":"10.1007\/s00228-011-1093-5","type":"journal-article","created":{"date-parts":[[2011,7,6]],"date-time":"2011-07-06T09:34:37Z","timestamp":1309944877000},"page":"55-64","source":"Crossref","is-referenced-by-count":102,"title":["Do CYP2D6 genotypes reflect oxycodone requirements for cancer patients treated for cancer pain? A cross-sectional multicentre study"],"prefix":"10.1007","volume":"68","author":[{"given":"Trine Naalsund","family":"Andreassen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingrid","family":"Eftedal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P\u00e5l","family":"Klepstad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Davies","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristin","family":"Bjordal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Staffan","family":"Lundstr\u00f6m","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stein","family":"Kaasa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ola","family":"Dale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2011,7,7]]},"reference":[{"key":"1093_CR1","unstructured":"World Health Organization (2010) WHO Pain ladder. http:\/\/www.who.int\/cancer\/palliative\/painladder\/en\/ . Accessed March 2011"},{"issue":"46","key":"1093_CR2","first-page":"3173","volume":"172","author":"L Jarlbaek","year":"2010","unstructured":"Jarlbaek L, Kehlet H, Sjogren P (2010) Det legale opioidforbrug I Danmark (The licit opioid consumption in Denmark). Ugeskrift for Laeger 172(46):3173\u20133178","journal-title":"Ugeskrift for Laeger"},{"issue":"9","key":"1093_CR3","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1016\/j.ejpain.2008.11.006","volume":"13","author":"K Hamunen","year":"2009","unstructured":"Hamunen K, Paakkari P, Kalso E (2009) Trends in opioid consumption in the Nordic countries 2002\u20132006. Eur J Pain 13(9):954\u2013962","journal-title":"Eur J Pain"},{"key":"1093_CR4","volume-title":"Legemiddelstatistikk 2010:2","author":"C Berg","year":"2010","unstructured":"Berg C, Furu K, Litleskare I, R\u00f8nning M, Sakshaug S, Selmer R, Skurtveit S, Str\u00f8m H (2010) Reseptregisteret 2005\u20132009. In: R\u00f8nning M (ed) Legemiddelstatistikk 2010:2. Nasjonalt folkehelseinstitutt, Nydalen"},{"issue":"6","key":"1093_CR5","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1093\/jat\/27.6.346","volume":"27","author":"KA Moore","year":"2003","unstructured":"Moore KA, Ramcharitar V, Levine B, Fowler D (2003) Tentative identification of novel oxycodone metabolites in human urine. J Anal Toxicol 27(6):346\u2013352","journal-title":"J Anal Toxicol"},{"key":"1093_CR6","first-page":"133","volume-title":"Casarett and Doull\u2019s toxicology, vol 6","author":"A Parkinson","year":"2001","unstructured":"Parkinson A, Ogilvie BW (2001) Biotransformation of xenobiotics. In: Klaassen CD (ed) Casarett & Doull\u2019s toxicology, vol 6. McGraw-Hill, New York, pp 133\u2013224"},{"issue":"3","key":"1093_CR7","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/S0009-9236(99)70037-8","volume":"66","author":"SE Ball","year":"1999","unstructured":"Ball SE, Scatina J, Kao J, Ferron GM, Fruncillo R, Mayer P, Weinryb I, Guida M, Hopkins PJ, Warner N, Hall J (1999) Population distribution and effects on drug metabolism of a genetic variant in the 5\u2032 promoter region of CYP3A4. Clin Pharmacol Ther 66(3):288\u2013294","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"1093_CR8","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1067\/mcp.2000.108506","volume":"68","author":"C Wandel","year":"2000","unstructured":"Wandel C, Witte JS, Hall JM, Stein CM, Wood AJ, Wilkinson GR (2000) CYP3A activity in African American and European American men: population differences and functional effect of the CYP3A4*1B5'-promoter region polymorphism. Clin Pharmacol Ther 68(1):82\u201391","journal-title":"Clin Pharmacol Ther"},{"issue":"28","key":"1093_CR9","first-page":"3296","volume":"121","author":"O Spigset","year":"2001","unstructured":"Spigset O (2001) Cytokrom P-450-systemet (The cytochrome P-450 system). Tidsskr Nor Laegeforen 121(28):3296\u20133298","journal-title":"Tidsskr Nor Laegeforen"},{"issue":"1","key":"1093_CR10","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/s00210-003-0832-2","volume":"369","author":"UM Zanger","year":"2004","unstructured":"Zanger UM, Raimundo S, Eichelbaum M (2004) Cytochrome P450 2D6: overview and update on pharmacology, genetics, biochemistry. Naunyn Schmiedebergs Arch Pharmacol 369(1):23\u201337","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"issue":"4","key":"1093_CR11","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1111\/j.1533-2500.2007.00153.x","volume":"7","author":"A Foster","year":"2007","unstructured":"Foster A, Mobley E, Wang Z (2007) Complicated pain management in a CYP450 2D6 poor metabolizer. Pain Pract 7(4):352\u2013356","journal-title":"Pain Pract"},{"issue":"7","key":"1093_CR12","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.2217\/pgs.09.64","volume":"10","author":"PJ Jannetto","year":"2009","unstructured":"Jannetto PJ, Bratanow NC (2009) Utilization of pharmacogenomics and therapeutic drug monitoring for opioid pain management. Pharmacogenomics 10(7):1157\u20131167","journal-title":"Pharmacogenomics"},{"issue":"12","key":"1093_CR13","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1007\/s00228-008-0525-3","volume":"64","author":"K Goryachkina","year":"2008","unstructured":"Goryachkina K, Burbello A, Boldueva S, Babak S, Bergman U, Bertilsson L (2008) CYP2D6 is a major determinant of metoprolol disposition and effects in hospitalized Russian patients treated for acute myocardial infarction. Eur J Clin Pharmacol 64(12):1163\u20131173. doi: 10.1007\/s00228-008-0525-3","journal-title":"Eur J Clin Pharmacol"},{"issue":"4","key":"1093_CR14","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1097\/01.jcp.0000085421.74359.60","volume":"23","author":"J Leon de","year":"2003","unstructured":"De Leon J, Dinsmore L, Wedlund P (2003) Adverse drug reactions to oxycodone and hydrocodone in CYP2D6 ultrarapid metabolizers. J Clin Psychopharmacol 23(4):420\u2013421","journal-title":"J Clin Psychopharmacol"},{"issue":"5","key":"1093_CR15","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1016\/j.pain.2011.01.040","volume":"152","author":"P Klepstad","year":"2011","unstructured":"Klepstad P, Fladvad T, Skorpen F, Bjordal K, Caraceni A, Dale O, Davies A, Kloke M, Lundstr\u00f6m S, Maltoni M, Radbruch L, Sabatowski R, Sigurdardottir V, Strasser F, Fayers PM, Kaasa S (2011) The influence from genetic variability on opioid use for cancer pain: a European study of 2294 cancer pain patients. Pain 152(5):1139\u20131145","journal-title":"Pain"},{"issue":"2","key":"1093_CR16","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/0304-3959(83)90143-4","volume":"17","author":"RL Daut","year":"1983","unstructured":"Daut RL, Cleeland CS, Flanery RC (1983) Development of the Wisconsin Brief Pain Questionnaire to assess pain in cancer and other diseases. Pain 17(2):197\u2013210","journal-title":"Pain"},{"issue":"3","key":"1093_CR17","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/0022-3956(75)90026-6","volume":"12","author":"MF Folstein","year":"1975","unstructured":"Folstein MF, Folstein SE, McHugh PR (1975) \u201cMini-mental state\u201d: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12(3):189\u2013198. doi: 10.1016\/0022-3956(75)90026-6","journal-title":"J Psychiatr Res"},{"issue":"9","key":"1093_CR18","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1111\/j.1532-5415.1992.tb01992.x","volume":"40","author":"TN Tombaugh","year":"1992","unstructured":"Tombaugh TN, McIntyre NJ (1992) The mini-mental state examination: a comprehensive review. J Am Geriatr Soc 40(9):922\u2013935","journal-title":"J Am Geriatr Soc"},{"issue":"2","key":"1093_CR19","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1017\/S0033291700046730","volume":"12","author":"JC Anthony","year":"1982","unstructured":"Anthony JC, LeResche L, Niaz U, von Korff MR, Folstein MF (1982) Limits of the \u2018Mini-Mental State\u2019 as a screening test for dementia and delirium among hospital patients. Psychol Med 12(2):397\u2013408","journal-title":"Psychol Med"},{"issue":"4","key":"1093_CR20","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1002\/1097-0142(194811)1:4<634::AID-CNCR2820010410>3.0.CO;2-L","volume":"1","author":"DA Karnofsky","year":"1948","unstructured":"Karnofsky DA, Abelmann WH, Craver LF, Burchenal JH (1948) The use of the nitrogen mustards in the palliative treatment of carcinoma. Cancer 1(4):634\u2013656","journal-title":"Cancer"},{"issue":"5","key":"1093_CR21","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1093\/jnci\/85.5.365","volume":"85","author":"NK Aaronson","year":"1993","unstructured":"Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, Filiberti A, Flechtner H, Fleishman SB, de Haes JC (1993) The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 85(5):365\u2013376","journal-title":"J Natl Cancer Inst"},{"key":"1093_CR22","volume-title":"The EORTC QLQ C-30 Scoring Manual","author":"Fayers PM, Aaronson NK, Bjordal K, Groenvold M, Curran D, Bottomley A, on behalf of the EORTC Quality of Life Group","year":"2001","unstructured":"Fayers PM, Aaronson NK, Bjordal K, Groenvold M, Curran D, Bottomley A, on behalf of the EORTC Quality of Life Group (2001) The EORTC QLQ C-30 Scoring Manual, 3rd edn. European Organisation for Research and Treatment of Cancer, Brussels","edition":"3"},{"issue":"6","key":"1093_CR23","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1111\/j.1523-1755.2005.00365.x","volume":"67","author":"AS Levey","year":"2005","unstructured":"Levey AS, Eckardt KU, Tsukamoto Y, Levin A, Coresh J, Rossert J, De Zeeuw D, Hostetter TH, Lameire N, Eknoyan G (2005) Definition and classification of chronic kidney disease: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 67(6):2089\u20132100. doi: 10.1111\/j.1523-1755.2005.00365.x","journal-title":"Kidney Int"},{"issue":"Suppl","key":"1093_CR24","first-page":"F-FC142","volume":"11","author":"AS Levey","year":"2005","unstructured":"Levey AS, Coresh J, Greene T, Marsh J, Kusek J, Van Lente Medicine F (2005) Estimating glomerular filtration rate with a new equation: MDRD4 revised equation for use with IDMS-traceable serum creatinine. J Am Soc Nephrol 11(Suppl):F-FC142","journal-title":"J Am Soc Nephrol"},{"issue":"5","key":"1093_CR25","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1007\/s00228-010-0948-5","volume":"67","author":"TN Andreassen","year":"2011","unstructured":"Andreassen TN, Klepstad P, Davies A, Bjordal K, Lundstrom S, Kaasa S, Dale O (2011) Influences on the pharmacokinetics of oxycodone: a multicentre cross-sectional study in 439 adult cancer patients. Eur J Clin Pharmacol 67(5):493\u2013506. doi: 10.1007\/s00228-010-0948-5","journal-title":"Eur J Clin Pharmacol"},{"issue":"1","key":"1093_CR26","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/0014-5793(96)00779-X","volume":"392","author":"R Lovlie","year":"1996","unstructured":"Lovlie R, Daly AK, Molven A, Idle JR, Steen VM (1996) Ultrarapid metabolizers of debrisoquine: characterization and PCR-based detection of alleles with duplication of the CYP2D6 gene. FEBS Lett 392(1):30\u201334","journal-title":"FEBS Lett"},{"issue":"4","key":"1093_CR27","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1097\/00008571-199508000-00005","volume":"5","author":"VM Steen","year":"1995","unstructured":"Steen VM, Andreassen OA, Daly AK, Tefre T, Borresen AL, Idle JR, Gulbrandsen AK (1995) Detection of the poor metabolizer-associated CYP2D6(D) gene deletion allele by long-PCR technology. Pharmacogenetics 5(4):215\u2013223","journal-title":"Pharmacogenetics"},{"issue":"8 Pt 1","key":"1093_CR28","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1093\/clinchem\/46.8.1072","volume":"46","author":"M Hersberger","year":"2000","unstructured":"Hersberger M, Marti-Jaun J, Rentsch K, Hanseler E (2000) Rapid detection of the CYP2D6*3, CYP2D6*4, and CYP2D6*6 alleles by tetra-primer PCR and of the CYP2D6*5 allele by multiplex long PCR. Clin Chem 46(8 Pt 1):1072\u20131077","journal-title":"Clin Chem"},{"issue":"5","key":"1093_CR29","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1097\/00008571-199610000-00005","volume":"6","author":"T Stuven","year":"1996","unstructured":"Stuven T, Griese EU, Kroemer HK, Eichelbaum M, Zanger UM (1996) Rapid detection of CYP2D6 null alleles by long distance- and multiplex-polymerase chain reaction. Pharmacogenetics 6(5):417\u2013421","journal-title":"Pharmacogenetics"},{"key":"1093_CR30","doi-asserted-by":"crossref","first-page":"113","DOI":"10.2307\/1164979","volume":"1","author":"PA Games","year":"1976","unstructured":"Games PA, Howell JF (1976) Pairwise multiple comparison procedures with unequal N\u2019s and\/or variances: a Monte Carlo study. J Educ Stat 1:113\u2013125","journal-title":"J Educ Stat"},{"key":"1093_CR31","doi-asserted-by":"crossref","first-page":"626","DOI":"10.2307\/2283989","volume":"62","author":"Z \u0160id\u00e0k","year":"1967","unstructured":"\u0160id\u00e0k Z (1967) Rectangular confidence region for the means of multivariate normal distributions. J Am Stat Assoc 62:626\u2013633","journal-title":"J Am Stat Assoc"},{"issue":"2","key":"1093_CR32","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.jpainsymman.2009.07.010","volume":"39","author":"F Mayyas","year":"2010","unstructured":"Mayyas F, Fayers P, Kaasa S, Dale O (2010) A systematic review of oxymorphone in the management of chronic pain. J Pain Symptom Manage 39(2):296\u2013308. doi: 10.1016\/j.jpainsymman.2009.07.010","journal-title":"J Pain Symptom Manage"},{"issue":"5","key":"1093_CR33","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.clpt.2006.01.009","volume":"79","author":"B Lalovic","year":"2006","unstructured":"Lalovic B, Kharasch E, Hoffer C, Risler L, Liu-Chen LY, Shen DD (2006) Pharmacokinetics and pharmacodynamics of oral oxycodone in healthy human subjects: role of circulating active metabolites. Clin Pharmacol Ther 79(5):461\u2013479","journal-title":"Clin Pharmacol Ther"},{"key":"1093_CR34","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1007\/s00228-010-0948-5","volume":"67","author":"TN Andreassen","year":"2010","unstructured":"Andreassen TN, Klepstad P, Davies A, Bjordal K, Lundstr\u00f6m S, Kaasa S, Dale O (2010) Influences on the pharmacokinetics of oxycodone: a multicentre cross-sectional study in 439 adult cancer patients. Eur J Clin Pharm 67:493\u2013506. doi: 10.1007\/s00228-010-0948-5","journal-title":"Eur J Clin Pharm"},{"issue":"1","key":"1093_CR35","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1097\/00008571-200102000-00006","volume":"11","author":"R Lovlie","year":"2001","unstructured":"Lovlie R, Daly AK, Matre GE, Molven A, Steen VM (2001) Polymorphisms in CYP2D6 duplication-negative individuals with the ultrarapid metabolizer phenotype: a role for the CYP2D6*35 allele in ultrarapid metabolism? Pharmacogenetics 11(1):45\u201355","journal-title":"Pharmacogenetics"},{"issue":"2","key":"1093_CR36","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1111\/j.1399-6576.2009.02104.x","volume":"54","author":"ST Zwisler","year":"2010","unstructured":"Zwisler ST, Enggaard TP, Mikkelsen S, Brosen K, Sindrup SH (2010) Impact of the CYP2D6 genotype on post-operative intravenous oxycodone analgesia. Acta Anaesthesiol Scand 54(2):232\u2013240. doi: 10.1111\/j.1399-6576.2009.02104.x","journal-title":"Acta Anaesthesiol Scand"},{"issue":"4","key":"1093_CR37","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1111\/j.1476-5381.2010.00673.x","volume":"160","author":"CF Samer","year":"2010","unstructured":"Samer CF, Daali Y, Wagner M, Hopfgartner G, Eap CB, Rebsamen MC, Rossier MF, Hochstrasser D, Dayer P, Desmeules JA (2010) The effects of CYP2D6 and CYP3A activities on the pharmacokinetics of immediate release oxycodone. Br J Pharmacol 160(4):907\u2013918. doi: 10.1111\/j.1476-5381.2010.00673.x","journal-title":"Br J Pharmacol"},{"issue":"1","key":"1093_CR38","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.sjpain.2009.09.003","volume":"1","author":"KK Lemberg","year":"2010","unstructured":"Lemberg KK, Heiskanen TE, Neuvonen M, Kontinen VK, Neuvonen PJ, Dahl ML, Kalso EA (2010) Does co-administration of paroxetine change oxycodone analgesia: an interaction study in chronic pain patients. Scand J Pain 1(1):24\u201333. doi: 10.1016\/j.sjpain.2009.09.003","journal-title":"Scand J Pain"},{"issue":"4","key":"1093_CR39","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1111\/j.1742-7843.2009.00378.x","volume":"104","author":"ST Zwisler","year":"2009","unstructured":"Zwisler ST, Enggaard TP, Noehr-Jensen L, Pedersen RS, Mikkelsen S, Nielsen F, Brosen K, Sindrup SH (2009) The hypoalgesic effect of oxycodone in human experimental pain models in relation to the CYP2D6 oxidation polymorphism. Basic Clin Pharmacol Toxicol 104(4):335\u2013344. doi: 10.1111\/j.1742-7843.2009.00378.x","journal-title":"Basic Clin Pharmacol Toxicol"},{"issue":"4","key":"1093_CR40","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1111\/j.1476-5381.2010.00709.x","volume":"160","author":"CF Samer","year":"2010","unstructured":"Samer CF, Daali Y, Wagner M, Hopfgartner G, Eap CB, Rebsamen MC, Rossier MF, Hochstrasser D, Dayer P, Desmeules JA (2010) Genetic polymorphisms and drug interactions modulating CYP2D6 and CYP3A activities have a major effect on oxycodone analgesic efficacy and safety. Br J Pharmacol 160(4):919\u2013930. doi: 10.1111\/j.1476-5381.2010.00709.x","journal-title":"Br J Pharmacol"},{"issue":"6","key":"1093_CR41","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/S0009-9236(98)90051-0","volume":"64","author":"T Heiskanen","year":"1998","unstructured":"Heiskanen T, Olkkola KT, Kalso E (1998) Effects of blocking CYP2D6 on the pharmacokinetics and pharmacodynamics of oxycodone. Clin Pharmacol Ther 64(6):603\u2013611","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"1093_CR42","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1111\/j.1365-2125.2010.03653.x","volume":"70","author":"J Gronlund","year":"2010","unstructured":"Gronlund J, Saari TI, Hagelberg NM, Neuvonen PJ, Olkkola KT, Laine K (2010) Exposure to oral oxycodone is increased by concomitant inhibition of CYP2D6 and 3A4 pathways, but not by inhibition of CYP2D6 alone. Br J Clin Pharmacol 70(1):78\u201387. doi: 10.1111\/j.1365-2125.2010.03653.x","journal-title":"Br J Clin Pharmacol"},{"issue":"1","key":"1093_CR43","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s00228-010-0893-3","volume":"67","author":"O Kummer","year":"2011","unstructured":"Kummer O, Hammann F, Moser C, Schaller O, Drewe J, Krahenbuhl S (2010) Effect of the inhibition of CYP3A4 or CYP2D6 on the pharmacokinetics and pharmacodynamics of oxycodone. Eur J Clin Pharmacol 67(1):63\u201371; doi: 10.1007\/s00228-010-0893-3","journal-title":"Eur J Clin Pharmacol"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.springerlink.com\/index\/pdf\/10.1007\/s00228-011-1093-5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,6,21]],"date-time":"2020-06-21T01:07:37Z","timestamp":1592701657000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00228-011-1093-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,7,7]]},"references-count":43,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2012,1]]}},"alternative-id":["1093"],"URL":"https:\/\/doi.org\/10.1007\/s00228-011-1093-5","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,7,7]]}}}